Results 131 to 140 of about 17,658 (223)

Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen [PDF]

, 2020
openaire   +1 more source

Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model. [PDF]

ESMO Open
Tang L, Gao R, Yao J, Zhang W, Zhang Y, Zhang Y, Lu H, An C, Gui L.   +8 more
europepmc   +1 more source

The Efficacy and Safety of Nab-Paclitaxel Plus Anlotinib in Small-Cell Lung Cancer for Second-Line Therapy. [PDF]

Thorac Cancer
Tian LJ, Zhou FF, Dai M, Liu JL, Guo QS.
europepmc   +1 more source

Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate! [PDF]

J Gastrointest Oncol
Babiker HM.
europepmc   +1 more source

Efficacy of tislelizumab combined with nab-paclitaxel and nedaplatin in advanced esophageal squamous cell carcinoma and its impact on serum tumor markers. [PDF]

Am J Cancer Res
Huang R, Shen G, Zhang W, Lin Y, Huang Z, Dai Y, Lin Y, Zhang Y.   +7 more
europepmc   +1 more source

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study. [PDF]

EBioMedicine
Undurraga M, Lang N, Koessler T, Diciolla A, Di Marco M, Mach N, Raimond C, Genoud V, Du Bois V, Tille JC, Bornand A, Moore JS, Weiner M, Smekens L, Sandoval JL, Terzic J, Christinat Y, Veillard J, Tsantoulis P, Thoueille P, Mercier T, Monig S, Petignat P, Toso C, Decosterd L, Hübner M, Labidi-Galy I, Ris F.   +27 more
europepmc   +1 more source

Cisplatin/Nab-Paclitaxel/Pembrolizumab Regimen [PDF]

, 2020
openaire   +1 more source

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer. [PDF]

J Ovarian Res
Lai S, Lai S, Xu X, Huang W, Chen Q, He S, Xue H.   +6 more
europepmc   +1 more source

Gemcitabine plus nab-paclitaxel in Japan

Annals of Oncology, 2016
Tatsuya Ioka, Kazuhiro Katayama, Kazuyoshi Ookawa, Hidenori Takahashi, Teruki Teshima   +4 more
openaire   +1 more source

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). [PDF]

EClinicalMedicine
Taieb J, Pernot S, Thuillier F, Delattre A, Vo-Quang E, Petorin C, Bourgeois V, Tougeron D, Audemar F, Vitellius C, Mosser L, Desrame J, Di Fiore F, Rinaldi Y, Pellat A, Bolliet M, Watelle F, Perrier H, Dubreuil O, Lepage C, Bachet JB.   +20 more
europepmc   +1 more source